

2003 DRAFTING REQUEST

Senate Resolution

Received: **03/02/2004**

Received By: **pdykman**

Wanted: **Today**

Identical to LRB:

For: **Ronald Brown (608) 266-8546**

By/Representing: **Mnuk, Katie**

This file may be shown to any legislator: **NO**

Drafter: **pdykman**

May Contact:

Addl. Drafters:

Subject: **Legislature - miscellaneous res.
Memorials - to Congress**

Extra Copies: **DAK**

Submit via email: **YES**

Requester's email: **Sen.Brown@legis.state.wi.us**

Carbon copy (CC:) to:

Pre Topic:

No specific pre topic given

Topic:

Disparity in the international trade of brand name prescription drugs

Instructions:

See Attached

Drafting History:

<u>Vers.</u>	<u>Drafted</u>	<u>Reviewed</u>	<u>Typed</u>	<u>Proofed</u>	<u>Submitted</u>	<u>Jacketed</u>	<u>Required</u>
/?							
/1	pdykman 03/02/2004	wjackson 03/02/2004	jfrantze 03/02/2004	_____	sbasford 03/02/2004	lemery 03/02/2004	

FE Sent For:

<END>

2003 DRAFTING REQUEST

Senate Resolution

Received: 03/02/2004

Received By: pdykman

Wanted: Today

Identical to LRB:

For: Ronald Brown (608) 266-8546

By/Representing: Mnuk, Katie

This file may be shown to any legislator: NO

Drafter: pdykman

May Contact:

Addl. Drafters:

Subject: Legislature - miscellaneous res.
Memorials - to Congress

Extra Copies: DAK

Submit via email: YES

Requester's email: Sen.Brown@legis.state.wi.us

Carbon copy (CC:) to:

Pre Topic:

No specific pre topic given

Topic:

Disparity in the international trade of brand name prescription drugs

Instructions:

See Attached

Drafting History:

<u>Vers.</u>	<u>Drafted</u>	<u>Reviewed</u>	<u>Typed</u>	<u>Proofed</u>	<u>Submitted</u>	<u>Jacketed</u>	<u>Required</u>
/?							
/1	pdykman 03/02/2004	wjackson 03/02/2004	jfrantze 03/02/2004	_____	sbasford 03/02/2004		

FE Sent For:

<END>

2003 DRAFTING REQUEST

Senate Resolution

Received: 03/02/2004

Received By: pdykman

Wanted: Today

Identical to LRB:

For: Ronald Brown (608) 266-8546

By/Representing: Mnuk, Katie

This file may be shown to any legislator: NO

Drafter: pdykman

May Contact:

Addl. Drafters:

Subject: Legislature - miscellaneous res.
Memorials - to Congress

Extra Copies: DAK

Submit via email: YES

Requester's email: Sen.Brown@legis.state.wi.us

Carbon copy (CC:) to:

Pre Topic:

No specific pre topic given

Topic:

Disparity in the international trade of brand name prescription drugs

Instructions:

See Attached

Drafting History:

<u>Vers.</u>	<u>Drafted</u>	<u>Reviewed</u>	<u>Typed</u>	<u>Proofed</u>	<u>Submitted</u>	<u>Jacketed</u>	<u>Required</u>
1?	pdykman	1 WJ 3/2	2/3/2	2/Pg 3/2			

FE Sent For:

<END>



2003 SENATE RESOLUTION

Tves

1 **Relating to:** strongly urging Congress and the Administration to address the
2 significant price disparity in the international trade of brand name prescription
3 drugs by creating a safe and legitimate program for prescription drug
4 importation or through negotiated trade agreements with other industrialized
5 nations.

6 Whereas, the practice of medicine has undergone a shift toward utilization of
7 outpatient prescription medications for patients who in previous years would have
8 been hospitalized, and therefore prescription drug spending is increasing over that
9 period; and

10 Whereas, prescription drug spending in the United States is increasing by up
11 to ^{2 12} ~~twelve~~ percent each year and accounts for approximately ^{2 11} ~~eleven~~ percent of all
12 health care spending, exceeding \$200 billion in outpatient prescription drugs in
13 2003; and

1 Whereas, Americans pay drug prices that are 30 to 300 percent higher than that
2 paid for the same drugs in Europe and other industrialized nations, and Canadian
3 drug prices average 68 percent less than American prices; and

4 Whereas, the United States provides the world's greatest financial support for
5 discovery of new medicines through research grants; and

6 Whereas, individuals who pay high prices for prescription drugs may leave
7 their prescriptions unfilled, thereby compromising their health and leading to more
8 costly medical intervention; and

9 Whereas, many consumers are seeking less expensive prescription drugs by
10 importing them from other countries; and

11 Whereas, the importation of prescription drugs by U.S. businesses and
12 consumers is illegal and potentially unsafe because such practice occurs outside all
13 state and federal regulations governing manufacture, distribution, and dispensing
14 of prescription medicines in this country; and

15 Whereas, all U.S. health care consumers must be assured of a safe and secure
16 system of prescription drug distribution; and

17 Whereas, licensed and regulated local professionals must remain a critical part
18 of our drug distribution infrastructure; and

19 Whereas, all purchasers of prescription drugs, including individual consumers,
20 managed care organizations, insurers, and employers, would benefit from a
21 reduction in the cost of prescription drugs in the U.S. now, therefore, be it

22 ***Resolved by the senate, That*** the Wisconsin senate petitions Congress and
23 the Administration to implement a system to allow licensed U.S. pharmacies and
24 distributors to participate in the importation of medications from pharmacies and
25 pharmaceutical wholesalers licensed and regulated in a manner deemed comparable

1 to the United States, enabling Wisconsin consumers to access lower-cost drugs while
2 obtaining medicines from local providers; and, be it further

3 **Resolved, That** the senate chief clerk ^{shall} provide a copy of this resolution to the
4 ~~President of the United States, the Secretary of the U.S. Department of Health and~~
5 ~~Human Services, the Secretary of the Wisconsin Department of Health and Family~~
6 ~~Services, and to all members of Wisconsin's congressional delegation.~~

7

(END)

Basford, Sarah

From: Mnuk, Katie
Sent: Tuesday, March 02, 2004 2:12 PM
To: LRB.Legal
Subject: Draft review: LRB 03-4402/1 Topic: Disparity in the international trade of brand name prescription drugs

It has been requested by <Mnuk, Katie> that the following draft be jacketed for the SENATE:

Draft review: LRB 03-4402/1 Topic: Disparity in the international trade of brand name prescription drugs